About US
Contact us
-
Medicare takes $4.5B cost hit from superstar hep C treatmentsIndustry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up? Some $4.5 billion2015/3/31
-
Baxter pays execs more than $8.5M to stick it out through pharma spinoffBaxter ($BAX) chief Robert Parkinson--who makes a perennial appearance on the list of the top-paid helmsman in biopharma--is in prime position to return this year, despite a drop in his overall compen2015/3/30
-
Eisai gets EMA nod for Lenvima just weeks after FDA approvalEisaihas gotten its second dose of good news in as many months. Weeks after getting anFDAapproval for its thyroid cancer drug Lenvima, the struggling Japanese drugmaker has gotten the nod for the pote2015/3/30
-
Hey, European countries--join forces to bring down drug prices, WHO suggestsYou want to reduce high prices for new meds, European countries? Here's a suggestion for you: Work together. According to a new study from the World Health Organization (WHO), it's becoming increasin2015/3/27
-
Dr. Reddy's shopping for deals up to $1B as it expands in injectable medsDr. Reddy's Laboratoriesis eyeing deals as big as $1 billion to build up its portfolio of higher-end products, including generic injectable drugs, and expand its footprint in emerging markets.2015/3/27
-
Amoun Pharma investors make another run at a $700M-plus saleIt's try, try again for Egypt-basedAmoun Pharmaceuticals. The drugmaker, among the largest in its home country, hired Goldman Sachs to look for potential buyers after previous efforts failed. AsBloom2015/3/26
-
Geriatrics experts call for halt to Low-T consumer adsA couple of geriatrics experts have joined the chorus of recommendations againsttestosteronetherapy. But they're going a step further. They say drugmakers' enthusiastic advertising--which happened to2015/3/26
-
Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trialAdvantage Merck ($MRK) in the melanoma immunotherapy race. The U.S.-based company says its PD-1 drugKeytrudamet its goals in a head-to-head study with Bristol-Myers Squibb's ($BMY)Yervoy(ipilimumab),2015/3/25
-
Which diseases are driving drug spending hikes? It's not just hep CIndustry watchers well know that U.S. drug spending is rising--a lot. And they also know that it's likely to continue over the next few years if some major changes don't occur. But which medical condi2015/3/25
-
With MenB vaccine Bexsero in hand, GSK aims for a price deal in EnglandNovartis ($NVS) may have spent 7 months negotiating fruitlessly with the U.K. government over the price of meningitis B vaccine Bexsero, but now that the product is in GlaxoSmithKline's ($GSK) hands,2015/3/24